Source: Pulse2.0

OncoImmune: Why Merck (MRK) Is Buying OncoImmune For $425 Million

Merck recently announced it is buying OncoImmune for $425 million in cash. These are the details about the deal. The post Why Merck (MRK) Is Buying OncoImmune For $425 Million appeared first on Pulse 2.0.

Read full article »
OncoImmune's Competitors | OncoImmune's News | OncoImmune's Financials
Stay up-to-date with the latest news on OncoImmune
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
Yang Liu's photo - Chairman & CEO of OncoImmune

Chairman & CEO

Yang Liu

CEO Approval Rating

89/100

Read more
Stay up-to-date with the latest news on OncoImmune